AAAAAA
Results: 26-50/72
Authors:
Kollmannsberger, C
Nichols, C
Bamberg, M
Hartmann, JT
Schleucher, N
Beyer, J
Schoffski, P
Derigs, G
Ruther, U
Bohlke, I
Schmoll, HJ
Kanz, L
Bokemeyer, C
Citation: C. Kollmannsberger et al., First-line high-dose chemotherapy +/- radiation therapy in patients with metastatic germ-cell cancer and brain metastases, ANN ONCOL, 11(5), 2000, pp. 553-559
Authors:
Bokemeyer, C
Kollmannsberger, C
Hartmann, JT
Kanz, L
Citation: C. Bokemeyer et al., Follow up after primary treatment: curable diseases treated non-surgically, ANN ONCOL, 11, 2000, pp. 73-78
Authors:
Bokemeyer, C
Hartmann, JT
Mayer, F
Bohlke, I
Kanz, L
von Pawel, J
Derigs, G
Schroder, M
Citation: C. Bokemeyer et al., UFT/leucovorin plus weekly paclitaxel in the treatment of solid tumors, ONCOLOGY-NY, 14(10), 2000, pp. 63-67
Authors:
Bokemeyer, C
Citation: C. Bokemeyer, Irinotecan - Clinical progress in the second-line therapy of advanced colorectal cancer, ONKOLOGIE, 23, 2000, pp. 28-31
Authors:
Kollmannsberger, C
Bokemeyer, C
Citation: C. Kollmannsberger et C. Bokemeyer, Therapy-related leukemia following high-dose chemotherapy: Compensating for the benefit?, ONKOLOGIE, 23(5), 2000, pp. 480-482
Authors:
Bokemeyer, C
Citation: C. Bokemeyer, Wilsede School for Oncology and Hematology: Reviewing the years 1989-1999, ONKOLOGIE, 23(3), 2000, pp. 282-282
Authors:
Einsele, H
Hebart, H
Kauffman-Schneider, C
Sinzger, C
Jahn, G
Bader, P
Klingebiel, T
Dietz, K
Loffler, J
Bokemeyer, C
Muller, CA
Kanz, L
Citation: H. Einsele et al., Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection, BONE MAR TR, 25(7), 2000, pp. 757-763
Authors:
Hartmann, JT
Fels, LM
Franzke, A
Knop, S
Renn, M
Maess, B
Panagiotou, P
Lampe, H
Kanz, L
Stolte, H
Bokemeyer, C
Citation: Jt. Hartmann et al., Comparative study of the acute nephrotoxicity from standard dose cisplatin+/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide, ANTICANC R, 20(5C), 2000, pp. 3767-3773
Authors:
Hartmann, JT
Kanz, L
Bokemeyer, C
Citation: Jt. Hartmann et al., Phase II study of continuous 120-hour- infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent gastrointestinal adenocarcinoma, ANTICANC R, 20(2B), 2000, pp. 1177-1182
Authors:
Souchon, R
Krege, S
Schmoll, HJ
Albers, P
Beyer, J
Bokemeyer, C
Classen, J
Dieckmann, KP
Hartmann, M
Heidenreich, A
Holtl, W
Kliesch, S
Kohrmann, KU
Kuczyk, M
Schmidberger, H
Weinknecht, S
Winter, E
Wittekind, C
Bamberg, M
Citation: R. Souchon et al., Interdisciplinary consensus on diagnosis and treatment of testicular germ cell tumors. Results of an update conference based on evidence-based medicine (EBM), STRAH ONKOL, 176(9), 2000, pp. 388-405
Authors:
Hartmann, JT
Fels, LM
Knop, S
Stolte, H
Kanz, L
Bokemeyer, C
Citation: Jt. Hartmann et al., A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors, INV NEW DR, 18(3), 2000, pp. 281-289
Authors:
Hartmann, JT
Bokemeyer, C
Citation: Jt. Hartmann et C. Bokemeyer, Diarrhea and constipation, ANTIB CHEMY, 50, 2000, pp. 184-188
Authors:
Hartmann, JT
Nichols, CR
Droz, JP
Horwich, A
Gerl, A
Fossa, SD
Beyer, J
Pont, J
Einhorn, L
Kanz, L
Bokemeyer, C
Citation: Jt. Hartmann et al., The relative risk of second nongerminal malignancies in patients with extragonadal germ cell tumors, CANCER, 88(11), 2000, pp. 2629-2635
Authors:
Kollmannsberger, C
Quietzsch, D
Haag, C
Lingenfelser, T
Schroeder, M
Hartmann, JT
Baronius, W
Hempel, V
Clemens, M
Kanz, L
Bokemeyer, C
Citation: C. Kollmannsberger et al., A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer, BR J CANC, 83(4), 2000, pp. 458-462
Authors:
Roelofs, H
Mostert, MC
Pompe, K
Zafarana, G
van Oorschot, M
van Gurp, RJHLM
Gillis, AJM
Stoop, H
Beverloo, B
Oosterhuis, JW
Bokemeyer, C
Looijenga, LHJ
Citation: H. Roelofs et al., Restricted 12p amplification and RAS mutation in human germ cell tumors ofthe adult testis, AM J PATH, 157(4), 2000, pp. 1155-1166
Authors:
Kollmannsberger, C
Kuzcyk, M
Mayer, F
Hartmann, JT
Kanz, L
Bokemeyer, C
Citation: C. Kollmannsberger et al., Late toxicity following curative treatment of testicular cancer, SEM SURG ON, 17(4), 1999, pp. 275-281
Authors:
Kuczyk, MA
Machtens, S
Bokemeyer, C
Hradil, K
Macheel, I
Jetscho, V
Hartmann, J
Thon, WF
Jonas, U
Serth, J
Citation: Ma. Kuczyk et al., Prognostic value of p27(Kip1) and p21(WAF/Cip) protein expression in muscle invasive bladder cancer, ONCOL REP, 6(3), 1999, pp. 687-693
Authors:
Serth, J
Kuczyk, M
Machtens, S
Bokemeyer, C
Herrmann, R
Hartmann, J
Knuchel, R
Jonas, U
Citation: J. Serth et al., Analysis of the cyclin-dependent kinase inhibitor p27(Kip1) in muscle invasive bladder cancer, ONCOL REP, 6(1), 1999, pp. 229-233
Authors:
Hartmann, JT
Quietzsch, D
Daikeler, T
Kollmannsberger, C
Mayer, F
Kanz, L
Bokemeyer, C
Citation: Jt. Hartmann et al., Mitomycin C continuous infusion as salvage chemotherapy in pretreated patients with advanced gastric cancer, ANTI-CANC D, 10(8), 1999, pp. 729-733
Authors:
Kollmannsberger, C
Brugger, W
Hartmann, JT
Maurer, F
Bohm, P
Kanz, L
Bokemeyer, C
Citation: C. Kollmannsberger et al., Phase II study of oral trofosfamide as palliative therapy in pretreated patients with metastatic soft-tissue sarcoma, ANTI-CANC D, 10(5), 1999, pp. 453-456
Authors:
Kollmannsberger, C
Pressler, H
Mayer, F
Kanz, L
Bokemeyer, C
Citation: C. Kollmannsberger et al., Cisplatin-refractory, HER2/neu-expressing germ-cell cancer: Induction of remission by the monoclonal antibody Trastuzumab, ANN ONCOL, 10(11), 1999, pp. 1393-1394
Authors:
Bokemeyer, C
Hartmann, JT
Kollmannsberger, C
Mayer, F
Kanz, L
Citation: C. Bokemeyer et al., UFT/calcium folinate plus weekly paclitaxel for solid tumors, ONCOLOGY-NY, 13(7), 1999, pp. 106-111
Authors:
Bokemeyer, C
Gerl, A
Schoffski, P
Harstrick, A
Niederle, N
Beyer, J
Casper, J
Schmoll, HJ
Kanz, L
Citation: C. Bokemeyer et al., Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer, J CL ONCOL, 17(2), 1999, pp. 512-516
Authors:
Bokemeyer, C
Kollmannsberger, C
Meisner, C
Harstrick, A
Beyer, J
Metzner, B
Hartmann, JT
Schmoll, HL
Einhorn, L
Kanz, L
Nichols, C
Citation: C. Bokemeyer et al., First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis, J CL ONCOL, 17(11), 1999, pp. 3450-3456
Authors:
Hartmann, JT
Kuczyk, MA
Kollmannsberger, C
Kanz, L
Bokemeyer, C
Citation: Jt. Hartmann et al., Future prospects in the chemotherapy of metastatic nonseminomatous testicular germ-cell cancer, WORLD J URO, 17(5), 1999, pp. 324-333